专题：Cancer Treatment and Pharmacology

This cluster of papers focuses on the chemotherapy-induced peripheral neuropathy (CIPN) experienced by cancer patients, particularly in the context of breast cancer treatment. It covers various aspects such as the neurotoxic effects of taxanes and oxaliplatin, neuroprotective strategies, and the impact of CIPN on the quality of life of patients. Additionally, it discusses the use of microtubule-targeting agents like Eribulin Mesylate in cancer treatment.
最新文献
Impact of Population Pharmacogenomics on Cisplatin‐Induced Neurotoxicities in Testicular Cancer Survivors

article Full Text OpenAlex

Radiation Recall Dermatitis Following Capivasertib Administration

article Full Text OpenAlex

Fluoropyrimidines

article Full Text OpenAlex

Class Effect of SGLT2 Inhibitors Against Doxorubicin-Induced Cardiotoxicity via Regulating Adenosine Kinase Mediated-Cardiac Oxidative Stress

article Full Text OpenAlex

The synthesis of sphingomyelin-derived Paclitaxel protocol v1

preprint Full Text OpenAlex

Alucinaciones visuales por abstinencia al baclofeno oral

article Full Text OpenAlex

History informing the future of exercise oncology

review Full Text OpenAlex

The efficacy of acupuncture in the treatment of chemotherapy-induced peripheral neuropathy in cancer patients: a systematic review and meta-analysis

review Full Text OpenAlex

Pyridostigmine and IVIG-Induced Coronary Vasospasm in Myasthenia Gravis: A Rarely Reported Side Effect of Treatment of MG

article Full Text OpenAlex

Combining antibody-drug conjugates with immune checkpoint inhibitors: A new paradigm for breast cancer therapy

review Full Text OpenAlex

近5年高被引文献
Pharmacological Reviews

review Full Text OpenAlex 2662 FWCI5.113

Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

article Full Text OpenAlex 1134 FWCI90.502

Doxorubicin-induced cardiotoxicity: An update on the molecular mechanism and novel therapeutic strategies for effective management

review Full Text OpenAlex 640 FWCI27.641

Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial

article Full Text OpenAlex 473 FWCI64.856

Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials

article Full Text OpenAlex 439 FWCI36.931

Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C

article Full Text OpenAlex 361 FWCI49.499

Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma

article Full Text OpenAlex 359 FWCI73.925

Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer

review Full Text OpenAlex 349 FWCI8.672

NCCN Guidelines® Insights: Breast Cancer, Version 4.2023

article Full Text OpenAlex 335 FWCI74.464

Laser soliton microcombs heterogeneously integrated on silicon

article Full Text OpenAlex 331 FWCI28.322